2552 Stock Overview
Operates as a drug development company that focuses on therapies for the treatment of diabetes in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2552 from our risk checks.
Hua Medicine (Shanghai) Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.58 |
52 Week High | HK$2.78 |
52 Week Low | HK$1.29 |
Beta | 1.57 |
1 Month Change | -0.63% |
3 Month Change | -1.86% |
1 Year Change | -32.77% |
3 Year Change | -69.38% |
5 Year Change | -77.13% |
Change since IPO | -80.92% |
Recent News & Updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Shareholder Returns
2552 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 3.3% | -2.7% | 1.3% |
1Y | -32.8% | -8.3% | 1.6% |
Return vs Industry: 2552 underperformed the Hong Kong Pharmaceuticals industry which returned -8.3% over the past year.
Return vs Market: 2552 underperformed the Hong Kong Market which returned 1.6% over the past year.
Price Volatility
2552 volatility | |
---|---|
2552 Average Weekly Movement | 6.5% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 7.5% |
10% most volatile stocks in HK Market | 15.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2552 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2552's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 177 | Li Chen | www.huamedicine.com |
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes.
Hua Medicine (Shanghai) Ltd. Fundamentals Summary
2552 fundamental statistics | |
---|---|
Market cap | HK$1.55b |
Earnings (TTM) | -HK$227.76m |
Revenue (TTM) | HK$82.60m |
18.8x
P/S Ratio-6.8x
P/E RatioIs 2552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2552 income statement (TTM) | |
---|---|
Revenue | CN¥76.61m |
Cost of Revenue | CN¥39.24m |
Gross Profit | CN¥37.37m |
Other Expenses | CN¥248.61m |
Earnings | -CN¥211.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.22 |
Gross Margin | 48.78% |
Net Profit Margin | -275.73% |
Debt/Equity Ratio | 122.6% |
How did 2552 perform over the long term?
See historical performance and comparison